Neuroendocrine tumors of the gastrointestinal tract: A decade of experience at the princess margaret hospital

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 1, 2008, Pages 64-70

  Rothenstein, Jeff ^a   Cleary, Sean P ^b   Pond, Gregory R ^b   Dale, Darlene ^b   Gallinger, Steven ^b   Moore, Malcolm J ^a   Brierley, James ^a   Siu, Lillian L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Department of Hepatobiliary Surgery ^*

Author keywords

Gastrointestinal tract; Neuroendocrine tumors

Indexed keywords

DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; OCTREOTIDE; PLATINUM; STREPTOZOCIN;

ADULT; ANATOMICAL VARIATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CARCINOID; CLINICAL FEATURE; COHORT ANALYSIS; DEMOGRAPHY; DISTANT METASTASIS; EXPERIENCE; FEMALE; FOLLOW UP; GASTROINTESTINAL TUMOR; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDGUT; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PANCREAS ISLET CELL TUMOR; PREDICTOR VARIABLE; PROGNOSIS; RETROSPECTIVE STUDY; SMALL CELL CARCINOMA; SURVIVAL RATE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME;

ADENOMA, ISLET CELL; CARCINOID TUMOR; CARCINOMA, SMALL CELL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 42449124155     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31807a2f49     Document Type: Article

References (44)

1. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours. Gut. 2005;54(suppl 4):1-16.
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959.
3. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001; 92:2204-2210.
4. Maggard MA, O'Connell JB, Ko CY. Updated population based review of carcinoid tumors. Ann Surg. 2004;240:117-122.
5. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long acting formulation versus open label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600-606.
6. Oberg K, Funa K, Alm G. Effects of leukocyte interferon upon clinical symptoms and hormone levels in patients with midgut carcinoid tumors and the carcinoid syndrome. N Engl J Med. 1983;309:129-133.
7. Bajetta E, Zilembo N, Di Bartolomeo M, et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferonalpha-2a. Cancer. 1993;72:3099-3105.
8. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25: 458-511.
9. Di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: a study by the Italian Trials in Medical Oncology Group. Cancer. 1996;77:402-408.
10. Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717-1751.
11. Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol. 1989;7:865-868.
12. Panzuto F, Di Fonzo M, Iannicelli E, et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. 2006;17:461-466.
13. Plockinger U, Wiedenmann B. Endocrine tumours of the gastrointestinal tract: management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol. 2005;19:553-576.
14. Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors: the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21:2689-2696.
15. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist. 2005;10:123-131.
16. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22: 4762-4771.
17. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519-523.
18. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29-37.
19. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13:572-581.
20. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8:685-690.
21. Pape UF, Bohmig M, Berndt U, et al. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center. Ann NY Acad Sci. 2004;1014:222-233.
22. Onaitis MW, Kirshbom PM, Hayward TZ, et al. Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg. 2000;232:549-556.
23. Shebani KO, Souba WW, Finkelstein DM, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg. 1999; 229:815-821.
24. de Groot V, Beckerman H, Lankhorst GJ, et al. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 2003;56:221-229.
25. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
26. Hall WH, Ramachandran R, Narayan S, et al. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer. 2004; 4:94.
27. Soreide JA, van Heerden JA, Thompson GB, et al. Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients. World J Surg. 2000;24:1431-1436.
28. Kirshbom PM, Kherani AR, Onaitis MW, et al. Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery. 1998;124:1063-1070.
29. Crocetti E, Paci E. Malignant carcinoids in the USA, SEER 1992-1999: an epidemiological study with 6830 cases. Eur J Cancer Prev. 2003;12: 191-194.
30. Sutton R, Doran HE, Williams EM, et al. Surgery for midgut carcinoid. Endocr Relat Cancer. 2003;10:469-481.
31. Hellman P, Lundström T, Ö hrvall U, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg. 2002;26:991-997.
32. Wängberg B, Westberg G, Tyle'n U, et al. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg. 1996;20:892-899.
33. Boudreaux JP, Putty B, Frey DJ, et al. Surgical treatment of advancedstage carcinoid tumors: lessons learned. Ann Surg. 2005;241:839-845.
34. Ahlman H. The role of surgery in patients with advanced midgut carcinoid tumours. Digestion. 1996;57(suppl 1):86-87.
35. Akerstrom G, Hellman P, Hessman O, et al. Management of midgut carcinoids. J Surg Oncol. 2005;89:161-169.
36. Woodside KJ, Townsend CM, Evers BM. Current management of gastrointestinal carcinoid tumors. J Gast Surg. 2004;8:742-756.
37. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89:151-160.
38. Clary B. Treatment of isolated neuroendocrine liver metastases. J Gastrointest Surg. 2006l;10:332-334.
39. Chen H, Hardacre JM, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187:88-92.
40. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000; 190:432-445.
41. Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227-232.
42. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer. 1999;86:944-948.
43. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials. 1979;2:327-334.
44. Engstrom PF, Lavin PT, Moertel CG, et al. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol. 1984;2:1255-1259.